Business Context and Reporting Period
This Form 8-K is a current report filed by Prothena Corporation plc on March 16, 2013. The filing discloses the appointment of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on director compensation details:
- Equity Grant: Option to purchase 50,000 ordinary shares, exercisable at the closing price on the grant date (March 18, 2013).
- Vesting Schedule: Full vesting on the first anniversary of appointment, contingent on continued service.
- Annual Retainer: Aggregate of $64,500, comprising $39,000 for director service, $10,000 for Ireland travel, and committee fees totaling $15,500 ($7,500 Audit, $5,000 Compensation, $3,000 Nominating).
- Payment Terms: Pro-rated for the remainder of 2013, paid in equal quarterly installments.
Material Changes
On March 16, 2013, the Board of Directors appointed Christopher S. Henney, Ph.D., D.Sc., as a director. He was immediately appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the specific compensation structure for the new director, which includes a travel allowance for Ireland-based board meetings.
Investor Verification Checklist
- Verify the closing share price on March 18, 2013, to determine the exercise price of the 50,000 share option grant.
- Confirm Dr. Henney's continued service status to validate the vesting of the initial equity grant.
- Review the press release filed as Exhibit 99.1 for additional context on the appointment.